Comparative Pharmacology
Head-to-head clinical analysis: PROMETH PLAIN versus PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETH PLAIN versus PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE.
PROMETH PLAIN vs PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative via blockade of central and peripheral H1 receptors and antagonism of dopamine D2 receptors. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia and cough suppression; it also has antitussive effects via central action.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
Promethazine hydrochloride 6.25-25 mg / codeine phosphate 10-20 mg (based on codeine component) orally every 4-6 hours as needed. Maximum codeine dose: 60 mg per dose, 120 mg per day.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Promethazine: 10-19 hours (terminal); Codeine: 2.4-4 hours (terminal), prolonged in hepatic impairment. Clinical context: Dosing interval typically 4-6 hours for codeine; promethazine accumulates with repeated dosing.
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Promethazine: Renal (70-80% as metabolites, <1% unchanged); Codeine: Renal (70-90% as metabolites, 5-15% unchanged). Biliary/feces: Minor (<10% total).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic